The Susan G. Komen Breast Cancer Foundation reported a 22 percent decline in contributions in fiscal 2013—totalling over $77 million—in recent financial statements.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
